Track Avalo Therapeutics's current cash ($25M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), AVTX shows a current cash of $25M. That compares with $130M in the prior-year period — down 80.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AVTX's current cash is now $25M (was $130M) — a 80.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avalo Therapeutics is outperforming or lagging.
Tracking AVTX's current cash over time shows whether Avalo Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $25M That compares with $130M in the prior-year period — down 80.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Avalo Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $25M) with ownership activity and broader fundamentals.
Avalo Therapeutics's current cash is $25M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.